A consortium formed by IVI RMA and GED Capital sealed an agreement with Fresenius to acquire Eugin for 500 million dollars, including earnings. The plan keeps Eugin’s operations in the United States and Canada under the IVI RMA umbrella, while the remainder of the business will remain with GED Capital. This strategic move positions IVI RMA to intensify its footprint in North America, aligning with a broader push to scale up in key markets where fertility treatment demand is robust and growing.
The acquisition marks a landmark expansion for IVI RMA, reinforcing its status as a leading global player in assisted reproductive treatments. It represents the first major maneuver under the leadership of Javier Sánchez Prieto, who stepped in as chief executive and has since steered a focused integration effort. In a statement, Prieto expressed enthusiasm about the transaction, emphasizing that Eugin’s United States and Canadian operations would be integrated into the IVI RMA group. He highlighted a shared philosophy of care and a commitment to delivering comprehensive and personalized treatment, with the aim of offering patients a world-class experience and consistently strong outcomes across the newly expanded network.
Eugin is recognized as one of the most influential operators in both the United States and Canada, and its portfolio includes the Boston IVF operations in the United States, Trio in Canada, and collaborative ties with Harvard Medical School. The business generates substantial revenue and contributes significantly to the group’s global reach, with total sales reported at around 150 million euros. The integration of these assets broadens IVI RMA’s ability to harmonize clinical expertise, research collaborations, and patient services across a larger geographic footprint, reinforcing the company’s leadership in reproductive medicine.
This deal follows IVI RMA’s previous acquisition of Conceptions, a prominent independent fertility operator in Colorado, expanding the company’s presence in the American market. Together, these acquisitions support a stated objective shared with the private equity group KKR: to become a dominant force across the United States and in major European markets where fertility services are concentrated. The expansion has positioned the American market as the most critical area for the group, contributing to a notable increase in annual sales and underscoring the strategic value of a cross-border platform that can leverage scale, standardization, and best practice sharing.
Since KKR joined IVI RMA earlier in the year, the company has experienced rapid growth, and the addition of Javier Sánchez-Prieto as chief executive has underscored a move toward greater professionalization and consolidation as a world leader in reproductive treatments. The founder, Antonio Pellicer, continues to guide the organization’s strategic priorities in science and innovation, ensuring that the group’s core strengths—clinical excellence, research partnerships, and patient-centered care—remain central to growth plans. The overall trajectory reflects a deliberate effort to harmonize operations and accelerate service delivery, with the aim of extending access to high-quality fertility care to more patients across North America and Europe.